Voronoi, Inc.

Equities

A310210

KR7310210000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
42,450 ^KRW	-7.31%		-12.02%	-21.39%

2023	Voronoi, Inc.(KOSDAQ:A310210) added to S&P Global BMI Index	CI
2023	Voronoi to Raise 45 Billion Won From Shares Issuance; Shares Jump 9%	MT

Voronoi, Inc. has completed an IPO in the amount of KRW 52 billion.

June 17, 2022 at 05:00 am

Voronoi, Inc. has completed an IPO in the amount of KRW 52 billion.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 325,000
PriceRange: KRW 40000

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 975,000
PriceRange: KRW 40000

Latest news about Voronoi, Inc.

Voronoi, Inc.(KOSDAQ:A310210) added to S&P Global BMI Index	18/09/23	CI
Voronoi to Raise 45 Billion Won From Shares Issuance; Shares Jump 9%	20/06/23	MT
Voronoi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Voronoi Signs $482 Million Deal to Develop Oral Kinase Inhibitor	15/09/22	MT
METiS Therapeutics Announces Pan-RAF Inhibitor License Agreement with Voronoi	13/09/22	CI
Voronoi, Inc. has completed an IPO in the amount of KRW 52 billion.	17/06/22	CI
Voronoi, Inc. has filed an IPO in the amount of KRW 59.8 billion.	13/05/22	CI
Voronoi, Inc. has withdrawn its IPO in the amount of KRW 130 billion.	16/03/22	CI
Voronoi, Inc. has filed an IPO.	30/08/21	CI
ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc	19/10/20	CI

Chart Voronoi, Inc.

Duration

Period

More charts

Company Profile

Voronoi Inc is a Korea-based company principally engaged in the research and development of new drug candidates. The Company is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The Company is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

42,450 KRW

Average target price

80,000 KRW

Spread / Average Target

+88.46%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VORONOI, INC.	-21.39%	531M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research